The National Institutes of Health (NIH) has halted its clinical trial of hydroxychloroquine, saying that while there are no ill side effects, the anti-malaria drug provides no benefit to COVID-19 patients.
“A data and safety monitoring board (DSMB) met late Friday and determined that while there was no harm, the study drug was very unlikely to be beneficial to hospitalized patients with COVID-19,” the NIH said in a statement.
It added, “The data from this study indicate that this drug provided no additional benefit compared to placebo control for the treatment of COVID-19 in hospitalized patients.”
Hydroxychloroquine, which has long been used to combat malaria, was heralded by many, including President Trump, as a possible treatment for the coronavirus until a working vaccine becomes available.
Read more at The Hill.